miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
Coralie Hoareau-Aveilla, Cathy Quelen, Annabelle Congras, Nina Caillet, Delphine Labourdette, Christine Dozier, Pierre Brousset, Laurence Lamant, Fabienne Meggetto
Haematologica February 2019 104: 347-359; doi:10.3324/haematol.2018.195131

Author Affiliations

  1. Coralie Hoareau-Aveilla1,2,3,*,
  2. Cathy Quelen1,2,3,*,
  3. Annabelle Congras1,2,3,§,
  4. Nina Caillet1,2,3,§,
  5. Delphine Labourdette4,
  6. Christine Dozier1,2,3,
  7. Pierre Brousset1,2,3,5,6,7,§,
  8. Laurence Lamant1,2,3,5,6,7,§ and
  9. Fabienne Meggetto1,2,3,5,6,7,§⇑
  1. 1Inserm, UMR1037 CRCT, F-31000 Toulouse, France
  2. 2Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
  3. 3CNRS, ERL5294 CRCT, F-31000 Toulouse, France
  4. 4Laboratoire d’Ingénierie des Systèmes Biologiques et des Procédés, Université de Toulouse, CNRS, INRA, INSA, Toulouse, France
  5. 5Institut Carnot Lymphome-CALYM, F-31024 Toulouse, France
  6. 6Laboratoire d’Excellence Toulouse Cancer-TOUCAN, F-31024 Toulouse, France
  7. 7European Research Initiative on ALK-Related Malignancies, Cambridge, UK
  1. Correspondence:
    fabienne.meggetto{at}inserm.fr
View Abstract

Article Information

vol. 104 no. 2 347-359
DOI 
https://doi.org/10.3324/haematol.2018.195131
PubMed 
30262555
Published By 
Haematologica
Print ISSN 
0390-6078
Online ISSN 
1592-8721
History 
  • Received April 9, 2018
  • Accepted September 21, 2018

Article Versions

Copyright & Usage 
Copyright © 2019 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

Author Information

  1. Coralie Hoareau-Aveilla1,2,3,*,
  2. Cathy Quelen1,2,3,*,
  3. Annabelle Congras1,2,3,§,
  4. Nina Caillet1,2,3,§,
  5. Delphine Labourdette4,
  6. Christine Dozier1,2,3,
  7. Pierre Brousset1,2,3,5,6,7,§,
  8. Laurence Lamant1,2,3,5,6,7,§ and
  9. Fabienne Meggetto1,2,3,5,6,7,§⇑
  1. 1Inserm, UMR1037 CRCT, F-31000 Toulouse, France
  2. 2Université Toulouse III-Paul Sabatier, UMR1037 CRCT, F-31000 Toulouse, France
  3. 3CNRS, ERL5294 CRCT, F-31000 Toulouse, France
  4. 4Laboratoire d’Ingénierie des Systèmes Biologiques et des Procédés, Université de Toulouse, CNRS, INRA, INSA, Toulouse, France
  5. 5Institut Carnot Lymphome-CALYM, F-31024 Toulouse, France
  6. 6Laboratoire d’Excellence Toulouse Cancer-TOUCAN, F-31024 Toulouse, France
  7. 7European Research Initiative on ALK-Related Malignancies, Cambridge, UK
  1. Correspondence:
    fabienne.meggetto{at}inserm.fr
View Abstract

Statistics from Altmetric.com

Article usage

Article usage: September 2018 to January 2019

AbstractFullPdf
Sep 20181301
Oct 2018125064
Nov 201843020
Dec 201825010
Jan 201985424
Back to top
Email
Print
Citation Tools

Jump To

What about you?
Tell us your interests and get all the new contents of Haematologica in advance